Attached files
file | filename |
---|---|
8-K - CURRENT REPORT - SANUWAVE Health, Inc. | snwv_8k.htm |
EX-10.1 - SEPARATION AGREEMENT - SANUWAVE Health, Inc. | snwv_ex101.htm |
Exhibit 99.1
SANUWAVE HEALTH PARTNERS WITH THE MOBILE HEALTH COMPANY, A NEW
COMPANY FORMED BY FORMER PRESIDENT SHRI PARIKH
SUWANEE, GA, May 18, 2020 - SANUWAVE Health,
Inc. (OTCQB: SNWV) is
pleased to announce they will be offering
dermaPACE®
System solutions to treat patients in
a home setting. SANUWAVE Health will also have devices placed with
THE MOBILE HEALTH COMPANY (MHC), a business recently formed by
former SANUWAVE President Shri Parikh.
SANUWAVE Health has quickly adapted to the changes occurring in the
world of wound care. Following on the announcement last week of 10
sites using dermaPACE mobile, SANUWAVE Health is pleased to
announce they are partnering with former President Shri Parikh, who
is launching a mobile solution to wound care and other treatments
directly to the patient’s home setting. In doing so, Shri
will be resigning from SANUWAVE as President, however, remains an
active company advisor. Shri comments, “I’m very
excited about this collaboration with SANUWAVE. What THE MOBILE
HEALTH COMPANY offers is particularly valuable now, a time where
patients are fearful and limited to getting essential care they
need. In Wound Care, amputation is an almost certain outcome for
DFU patients that go untreated. With MHC, we can offer continuous
care, in a safe and clean environment, with state of the art
technologies, such as dermaPACE, to reduce the systems’
chronic care costs burden, while improving patient compliance and
outcomes.” SANUWAVE CEO Kevin Richardson added, “We are
excited to partner with Shri and his new business model. I am
confident MHC will be an extremely successful venture which
SANUWAVE can grow with as MHC enters new regions around the
country”.
About SANUWAVE Health, Inc.
SANUWAVE Health, Inc. (OTCQB: SNWV) is a shockwave technology
company initially focused on the development and commercialization
of patented noninvasive, biological response activating devices for
the repair and regeneration of skin, musculoskeletal tissue and
vascular structures. SANUWAVE’s portfolio of regenerative
medicine products and product candidates activate biologic
signaling and angiogenic responses, producing new vascularization
and microcirculatory improvement, which helps restore the
body’s normal healing processes and regeneration. SANUWAVE
applies its patented PACE®
technology in wound healing,
orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead
product candidate for the global wound care market,
dermaPACE®,
is US FDA cleared for the treatment of Diabetic Foot Ulcers.
The device is also CE Marked throughout Europe and has device
license approval for the treatment of the skin and subcutaneous
soft tissue in Canada, South Korea, Australia and New Zealand.
SANUWAVE researches, designs, manufactures, markets and services
its products worldwide, and believes it has demonstrated that its
technology is safe and effective in stimulating healing in chronic
conditions of the foot (plantar fasciitis) and the elbow (lateral
epicondylitis) through its U.S. Class III PMA approved
OssaTron® device,
as well as stimulating bone and chronic tendonitis regeneration in
the musculoskeletal environment through the utilization of its
OssaTron, Evotron® and
orthoPACE® devices
in Europe, Asia and Asia/Pacific. In addition, there are
license/partnership opportunities for SANUWAVE’s shockwave
technology for non-medical uses, including energy, water, food and
industrial markets.
Forward-Looking Statements
This press release may contain “forward-looking
statements” within the meaning of the Private Securities
Litigation Reform Act of 1995, such as statements relating to
financial results and plans for future business development
activities, and are thus prospective. Forward-looking statements
include all statements that are not statements of historical fact
regarding intent, belief or current expectations of the Company,
its directors or its officers. Investors are cautioned that any
such forward-looking statements are not guarantees of future
performance and involve risks and uncertainties, many of which are
beyond the Company’s ability to control. Actual results may
differ materially from those projected in the forward-looking
statements. Among the key risks, assumptions and factors that may
affect operating results, performance and financial condition are
risks associated with the regulatory approval and marketing of the
Company’s product candidates and products, unproven
pre-clinical and clinical development activities, regulatory
oversight, the Company’s ability to manage its capital
resource issues, competition, and the other factors discussed in
detail in the Company’s periodic filings with the Securities
and Exchange Commission. The Company undertakes no obligation to
update any forward-looking statement.
For additional information about the Company, visit
www.sanuwave.com.
Contact:
Millennium
Park Capital LLC
Christopher
Wynne
312-724-7845
cwynne@mparkcm.com
SANUWAVE
Health, Inc.
Kevin
Richardson II
CEO and
Chairman of the Board
978-922-2447
investorrelations@sanuwave.com